At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 97 enrolled
Drug / intervention
Maxidex +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention
In Brief
A Phase 4 clinical trial evaluating Maxidex and No treatment for Sjogren's Syndrome. Completed, enrolled 97 participants across 2 sites.
Detailed Summary
The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSjogren's Syndrome
CountriesCanada
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedMar 2008
Primary CompletionFeb 2009
TodayJul 2026
First PostedMar 7, 2008
Enrollment StartFeb 1, 2008
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 18.3 years ago
Interventions
Maxidexdrug
Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
No treatmentother
Healthy normal control group receiving no treatment